Jun 9 |
Checking Into Cullinan Therapeutics
|
Jun 4 |
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green
|
Jun 3 |
Cullinan Therapeutics announces success for zipalertinib as combo therapy
|
Jun 1 |
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
|
May 24 |
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
|
May 23 |
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
|
May 16 |
Cullinan Therapeutics files to sell 14.4M shares of common stock for holders
|
May 16 |
Cullinan Therapeutics reports Q1 results
|
May 15 |
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
May 9 |
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
|